Author

Cheryl L. Selinsky

Observed names: C. Selinsky, Cheryl Selinski, Cheryl Selinsky, Selinsky, Cheryl Lynn, author

Institution: Parker Institute for Cancer Immunotherapy

Observed institutions: Translational Genomics Research Institute, St. Joseph's Hospital and Medical Center, Vical (United States), Parker Institute for Cancer Immunotherapy, Arizona State University, Colorado State University

ORCID: 0000-0002-8792-055X

Observed ORCID: 0000-0002-8792-055X

OpenAlex ID: A5013367239

Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction

2020 · Daniel K. Wells, Marit M. van Buuren, et al. · Cell · 534

PDF

CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study

2020 · Mark H O'Hara, Eileen M O'Reilly, et al. · The Lancet Oncology · 306

A DNA-Based Vaccine for the Prevention of Human Cytomegalovirus-Associated Diseases

2005 · C. Selinsky, C. Luke, et al. · Human Vaccines · 75

PDF

Abstract CT004: A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients

2019 · Mark H. O'Hara, Eileen M. O'Reilly, et al. · Cancer Research · 66

Identification of a Blood-Based Protein Biomarker Panel for Lung Cancer Detection

2020 · Victoria El-Khoury, Anna Schritz, et al. · Cancers · 29

PDF

Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults

2009 · Wendy A. Keitel, John J. Treanor, et al. · Human Vaccines · 25

PDF

Soluble Tumor Necrosis Factor Receptor Type I Enhances Tumor Development and Persistence in Vivo

2000 · Cheryl L. Selinsky, Mark D. Howell · Cellular Immunology · 18

2019 · Mark H. O'Hara, Eileen M. O'Reilly, et al. · Clinical Trials · 15

New classes of orthopoxvirus vaccine candidates by functionally screening a synthetic library for protective antigens

2009 · Alexandre Borovkov, D. Mitch Magee, et al. · Virology · 11

PDF

Qualification and performance characteristics of a quantitative enzyme-linked immunosorbent assay for human lgG antibodies to anthrax lethal factor antigen

2006 · Cheryl L. Selinsky, Vanessa D. Whitlow, et al. · Biologicals · 9

Baseline level and early on-treatment clearance of circulating mutant KRAS in metastatic pancreatic ductal adenocarcinoma treated with chemotherapy with or without immunotherapy.

2021 · Jacob E. Till, Aseel Abdalla, et al. · Journal of Clinical Oncology · 1

An exploratory study of nivolumab (nivo) with or without ipilimumab (ipi) according to the percentage of tumoral CD8 cells in advanced metastatic cancer.

2021 · Apostolia Maria Tsimberidou, Alexandra Drakaki, et al. · Journal of Clinical Oncology · 1

Advances in Techniques for Immunotherapy Biomarker Analysis

2021 · Theresa M. LaVallee, Pier Federico Gherardini, et al. · Springer Publishing Company eBooks

Abstract 3210: Strategies to improve the sensitivity and ranking ability of neoantigen prediction methods: Report on the results of the Tumor nEoantigen SeLection Alliance (TESLA)

2020 · Daniel K. Wells, Kristen Dang, et al. · Cancer Research

Abstract 5068: Identification of key tumorigenic pathways in never-smoker lung adenocarcinoma using massively parallel DNA and RNA sequencing and methylation profiling

2012 · Timothy G. Whitsett, Irene Cherni, et al. · Cancer Research

Abstract A43: Identification of key tumorigenic pathways in never-smoker lung adenocarcinoma patients using massively parallel DNA and RNA sequencing

2012 · Timothy G. Whitsett, Shripad Sinari, et al. · Clinical Cancer Research

The role of soluble tumor necrosis factor receptor type I in tumor survival

1999 · Selinsky, Cheryl Lynn, author, Howell, Mark, advisor

PDF

Works count: 17

Citation count: 1,089

H-index: 9

I10-index: 9